Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

Source Motley_fool

Key Points

  • Johnson & Johnson is a leader in the pharmaceutical and medical device sectors.

  • JNJ is a Dividend King with an above-market yield.

  • The healthcare giant's valuation could turn some investors away from the stock.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Johnson & Johnson (NYSE:JNJ) is the kind of investment that you buy and hold for the long term. However, that doesn't mean it will be a great option for every investor. While it could be a buy for a conservative dividend investor today, many others will likely be better off putting the stock on their wish list. Here's why.

Johnson & Johnson runs a great business

It is important to understand that Johnson & Johnson has an incredible business history. Founded more than 100 years ago, the business has proven resilient, changing over time to serve its customers and reward its shareholders. Today, the company is an industry leader in both the pharmaceutical and medical devices segments of the broader healthcare sector.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

A person holding up a king chess piece.

Image source: Getty Images.

There are many ways that J&J's success could be highlighted, but one of the best is probably its dividend track record. The healthcare giant has increased its dividend for 64 consecutive years. That not only makes J&J a Dividend King but also gives it the longest streak of any healthcare company. A company can't build a dividend track record like that by accident; it requires a strong business model that gets executed well in good times and bad.

During the third quarter, J&J again showed how well it is run, increasing its full-year guidance for revenues and earnings. On the top line, the healthcare behemoth now projects $101.2 billion in revenue, with the bottom line at $11.10 per share. Those are both modest improvements over the previous guidance, but the direction is what's important. If you own this stock, you should be pleased with the third-quarter 2026 update.

Who should own Johnson & Johnson?

The problem is that Wall Street knows that J&J is a well-run company. That's why the yield is 1.9%, above the market's tiny 1% and the average healthcare stock's 1.3%, but still unlikely to be enticing to investors looking to maximize the income their portfolios generate. The yield is also near its lowest levels in the past decade. That speaks to another problem: valuation.

Johnson & Johnson's price-to-sales ratio is 6.8x compared to a five-year average of 4.8x. Its price-to-earnings ratio is 42x, compared with a long-term average of 24x. And its price-to-book ratio is 8.2x versus a five-year average of 5.8x. While the P/E ratio has been biased higher by one-time charges, the overall statement here is that J&J is expensive. So value investors will probably want to stay on the sidelines.

There is, however, a place for Johnson & Johnson if you are a conservative, income-oriented investor who places a high value on dividend consistency. This is, basically, a situation where investors are paying up for quality. That said, if you are patient, you could probably buy the stock with a more attractive yield and valuation during a broad market downturn. So even here, it could be a wish-list stock. But if you are looking to buy a diversified healthcare stock that you can count on for the long term, it deserves strong consideration despite the premium price tag.

No investment is perfect, not even J&J

It would be wonderful if great companies were also cheap and had above-average dividend yields. That's just not how Wall Street works most of the time. If you have a value focus or favor high-yield stocks, J&J probably won't fit your portfolio right now. Keep it on your wish list, just in case a market downdraft opens up a buying opportunity. However, if what you are looking for is a reliable dividend stock with an above-market yield, paying a premium for J&J could still be worth it if you have a long enough time horizon.

Should you buy stock in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
Nov 20, Fri
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
Nov 20, Fri
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
Nov 20, Fri
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
Nov 20, Fri
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Gold and Bitcoin Are Falling. Peter Schiff Sees Opportunities for BothPeter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
Author  Beincrypto
Nov 20, Fri
Peter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
goTop
quote